arrow_back Back to App

Dialysis-Related Amyloidosis Treatment: New Medicare Coverage

This act introduces new Medicare benefits to cover the costs of treatments for dialysis-related amyloidosis. This means that individuals undergoing dialysis who develop this condition will have access to specialized therapies, potentially improving their quality of life and health.
Key points
Medicare will now cover treatments for dialysis-related amyloidosis.
Covered treatments include FDA-approved therapies and necessary adjunct supplies and services.
Payments for these treatments will be made separately at 100% of reasonable charges, distinct from standard dialysis fees.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4055
Sponsor: Rep. Babin, Brian [R-TX-36]
Process start date: 2025-06-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Dialysis-Related Amyloidosis Treatment Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4055.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-20.

What are the main provisions?

Key points include:

  • Medicare will now cover treatments for dialysis-related amyloidosis.
  • Covered treatments include FDA-approved therapies and necessary adjunct supplies and services.
  • Payments for these treatments will be made separately at 100% of reasonable charges, distinct from standard dialysis fees.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Babin, Brian [R-TX-36].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Benefits